FI120670B - Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö - Google Patents

Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö Download PDF

Info

Publication number
FI120670B
FI120670B FI964033A FI964033A FI120670B FI 120670 B FI120670 B FI 120670B FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 120670 B FI120670 B FI 120670B
Authority
FI
Finland
Prior art keywords
cells
formulated
medicament
sertoli
transplantation
Prior art date
Application number
FI964033A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964033A0 (fi
FI964033A (fi
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of FI964033A0 publication Critical patent/FI964033A0/fi
Publication of FI964033A publication Critical patent/FI964033A/fi
Application granted granted Critical
Publication of FI120670B publication Critical patent/FI120670B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI964033A 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö FI120670B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
US21169594 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts
US9504565 1995-04-13

Publications (3)

Publication Number Publication Date
FI964033A0 FI964033A0 (fi) 1996-10-08
FI964033A FI964033A (fi) 1996-12-12
FI120670B true FI120670B (fi) 2010-01-29

Family

ID=22787974

Family Applications (2)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (fi) 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Country Status (12)

Country Link
US (3) US5725854A (de)
EP (1) EP0755258B1 (de)
JP (1) JPH09512015A (de)
AT (1) ATE212230T1 (de)
AU (1) AU715177B2 (de)
CA (1) CA2187803C (de)
DE (1) DE69525151T2 (de)
DK (1) DK0755258T3 (de)
ES (1) ES2169128T3 (de)
FI (2) FI120670B (de)
NO (1) NO320713B1 (de)
WO (1) WO1995028167A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0801559B1 (de) * 1995-02-08 2002-04-24 Yamanouchi Europe B.V. Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen
EP0814819B1 (de) * 1995-03-13 2004-07-14 University Of South Florida Sertolizellen als transplantationunterstützer bei zelltransplantationen
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
AU759273B2 (en) * 1998-01-02 2003-04-10 Titan Pharmaceuticals, Inc. Use of retinal pigment epithelial cells for creation of an immune privilege site
ATE452643T1 (de) * 1998-11-06 2010-01-15 Sertoli Technologies Inc Herstellung eines biologischen faktors und schaffung einer immunologisch vorteilhaften umgebung unter verwendung genetisch veränderter sertolizellen
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
CZ302458B6 (cs) * 1998-12-15 2011-06-01 Universidad Nacional Autonoma De Mexico Zarízení pro implantaci biologického materiálu
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
EP1248640B1 (de) 2000-01-20 2006-10-04 Diabcell Pty Limited Präparation und xenotransplantation von inseln aus schweinen
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
CA2421036A1 (en) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
KR20030096381A (ko) * 2001-05-11 2003-12-24 오쏘-맥네일 파머슈티칼 인코퍼레이티드 동물에 사용하기 위한 면역 조절장치
WO2003027270A1 (en) * 2001-09-28 2003-04-03 Diabcell Pty Limited Growing xenotransplant material in culture
EP1476186A1 (de) * 2002-02-22 2004-11-17 Prophy Med AB Verwendung eines gewebefaktor-hemmers oder -antagonists
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
WO2004113516A1 (en) * 2003-06-24 2004-12-29 Diabcell Pty Limited Porcine islets cultured with porcine sertoli cells for xenotransplantation
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
US7910359B2 (en) 2004-07-29 2011-03-22 University Of Miami Hybrid device for cell therapies
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
WO2007089572A2 (en) * 2006-01-26 2007-08-09 John Constance M Proliferative primary human sertoli cell cultures and their applications
CA2658951A1 (en) * 2006-07-28 2008-01-31 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2009105278A2 (en) 2008-02-21 2009-08-27 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
KR102008762B1 (ko) 2009-08-28 2019-08-09 세르노바 코포레이션 세포 이식 방법 및 장치
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
WO2019079384A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System ADMINISTRATION DEVICES
US20220211770A1 (en) 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
AU2289395A (en) 1995-11-10
FI20085733A (fi) 2008-07-18
WO1995028167A1 (en) 1995-10-26
ATE212230T1 (de) 2002-02-15
FI120696B (fi) 2010-01-29
EP0755258A1 (de) 1997-01-29
CA2187803C (en) 1999-09-28
FI964033A0 (fi) 1996-10-08
US5843430A (en) 1998-12-01
DE69525151T2 (de) 2002-08-14
ES2169128T3 (es) 2002-07-01
CA2187803A1 (en) 1995-10-26
DK0755258T3 (da) 2002-05-13
DE69525151D1 (de) 2002-03-14
NO964342D0 (no) 1996-10-11
EP0755258B1 (de) 2002-01-23
US5759534A (en) 1998-06-02
FI964033A (fi) 1996-12-12
NO320713B1 (no) 2006-01-23
JPH09512015A (ja) 1997-12-02
NO964342L (no) 1996-12-13
AU715177B2 (en) 2000-01-20
US5725854A (en) 1998-03-10

Similar Documents

Publication Publication Date Title
FI120670B (fi) Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö
US5849285A (en) Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US5958404A (en) Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US8142769B2 (en) Preparation and xenotransplantation of porcine islets
EP1401282A1 (de) Stammzellendifferenzierung
Scharp et al. Isolating the elusive islet
Lacy et al. Prolongation of islet xenograft survival (rat to mouse)
Cameron et al. Post-thaw viability and functionality of cryopreserved rat fetal brain cells cocultured with Sertoli cells
JP5579270B2 (ja) 膵島と脂肪組織由来幹細胞を利用した膵島移植
US20020065212A1 (en) Methods of treating disease using sertoli cells and allografts or xenografts
Charles et al. Storage and microencapsulation of islets for transplantation
Karl et al. Transplantation of insulin-secreting tissues.
Peterson et al. Fetal islet transplantation: implications for diabetes
Horaguchi et al. Islet recovery in chronic pancreatitis
Walthall et al. Rodent xenografts of human and porcine fetal tissue
KR100354931B1 (ko) 췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법
Kojima et al. Culture of the islets of Langerhans for transplantation
Andersson et al. Experimental studies of transplantation and regeneration of endocrine pancreatic cells
McCullough et al. Human Islet Isolation and Transplantation
Özdamar The Effects Of Long-Term Parenteral Nutrition On Dog Pancreas: An Electron Microscopic Study
Mirbolooki et al. A perspective on clinical islet transplantation: past, present and developments for future
Jovanovic-Peterson et al. The Use of Human Fetal Islet Tissue for Adjunctive Treatment in Insulin-Dependent Diabetic Patients: The Case for “Partial Success”
AU2002312125A1 (en) Stem cell differentiation

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120670

Country of ref document: FI

MA Patent expired